Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Agreed Ignatius, it will be interesting to see if any changes are made to the BOD this year. Again, I wouldn't be surprised if Mayes' resignation was a nudge to begin to change ADXS' corporate governance to more institutional quality since there was a conflict of interest with there being two execs (DO and Mayes) serving on the BOD. As Funky has pointed to as well, if you look at the composition of the BOD, essentially a rubber stamp to allow DO to run ADXS like it is his own private company, that's not going to take us to the next level of valuation. Perhaps to date, investors like Adage and Broadfin have given DO the benefit of the doubt and let him run the company untouched because he has made a lot of process recapitalizing the company and setting up a great pipeline. But now we are at a cross roads, with investors across his offerings down 33%, while management has made out like bandits, thereby requiring intervention from our large investors to hold DO more accountable and align more with shareholder interests. All good, because the company has a great platform. We just need to better balance the fruits of the company's success so that investors partake moving forward, not just management as has been the case.